TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6120311

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (mean 683 mg; 10.4 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline
Number of subjects: 12
Study: 31980342

Group type: EXPERIMENTAL
Intervention: Experiential negative symptoms (anhedonia and avolition)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Alogia
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control for neurocognition, antipsychotic medication, and depressive symptoms
Number of subjects: 146
Study: 29807441

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 240
Study: 28688269

Group type: EXPERIMENTAL
Intervention: Horticulture therapy in specially designed urban green environments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occupational art therapy (control group)
Number of subjects: 30
Study: 25577543

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) with budesonide (400 µg)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Doxofylline (400 mg) with budesonide (400 µg)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Tiotropium (18 µg) with budesonide (400 µg)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Formoterol (12 µg) with budesonide (400 µg)
Number of subjects: 297
Study: 24088126

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21270383

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 18221822

Group type: EXPERIMENTAL
Intervention: Mushroom lunches (339 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meat lunches (783 kcal)
Number of subjects: 0
Study: 17215602

Group type: EXPERIMENTAL
Intervention: Programmed Information for Parental Coping before Intravenous Procedure (PIPC‐IP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 14653130

Group type: EXPERIMENTAL
Intervention: Tianlong Xifeng granule (TXG)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ginkgo Biloba capsule
Number of subjects: 182
Study: 11015996

Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (610 mg/m2/day x 10 days or over) preoperatively
Number of subjects: 171

Group type: COMPARATOR
Intervention: No treatment preoperatively (Group II)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (good compliance)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Oral 5'-DFUR (poor compliance)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients classified as having curability B (Group I)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Patients classified as having curability B (Group II)
Number of subjects: 171
Study: 9165564

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 1500 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ganciclovir 5 mg/kg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ganciclovir plus Mycophenolate mofetil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus Ganciclovir
Number of subjects: 12
Study: 1350482

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4001280

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 15 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29197219

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg/day of somatropin
Number of subjects: 48
Study: 26935819

Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) at a minimum dose of 2 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 25355697

Group type: EXPERIMENTAL
Intervention: Monthly or bimonthly standard 3-day treatment regimens of dihydroartemisinin-piperaquine
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Monthly dosing regimen based on the final model
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 23523459

Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 183

Group type: COMPARATOR
Intervention: PES
Number of subjects: 183
Study: 20888520

Group type: EXPERIMENTAL
Intervention: Testosterone transdermal patch (T group, n = 24)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (P group, n = 12)
Number of subjects: 36
Study: 18620759

Group type: EXPERIMENTAL
Intervention: Cold knife tonsillectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thermal welding tonsillectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Radiofrequency excision
Number of subjects: 90
Study: 16630899

Group type: EXPERIMENTAL
Intervention: Stereotactic hematoma evacuation (SHE)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 242
Study: 12744768

Group type: EXPERIMENTAL
Intervention: Linezolid (intravenous followed by optional oral)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Vancomycin (intravenous only)
Number of subjects: 230
Study: 12201213

Group type: EXPERIMENTAL
Intervention: Antithyroid treatment (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observation (Group 2)
Number of subjects: 20
Study: 10499052

Group type: EXPERIMENTAL
Intervention: Middle turbinate medialization
Number of subjects: 50
Study: 7580707

Group type: EXPERIMENTAL
Intervention: Extra information offered individually
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: Extra information offered in class
Number of subjects: 1691

Group type: COMPARATOR
Intervention: Control group (usual information)
Number of subjects: 1691
Study: 2022677

Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 6
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 8
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dangling protocol initiated on postoperative day 10
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dangling on postoperative day 6
Number of subjects: 22
Study: 7056011

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral theophylline for four weeks
Number of subjects: 20
Study: 31495220

Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 1840

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1840
Study: 28079022

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 26924470

Group type: EXPERIMENTAL
Intervention: eOIT (egg oral immunotherapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25086123

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 22085872

Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA, high FA group)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA, low FA group)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Enalapril only (10 mg, control group)
Number of subjects: 480
Study: 19640950

Group type: EXPERIMENTAL
Intervention: 160 mg anthocyanins twice daily for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17241190

Group type: EXPERIMENTAL
Intervention: Exercise Consultation Interview (ECI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 15619106

Group type: EXPERIMENTAL
Intervention: 1.74% THC (low dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.93% THC (high dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0% THC (placebo)
Number of subjects: 40
Study: 12138263

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 9482769

Group type: EXPERIMENTAL
Intervention: Quercetin-containing supplement (1.0 g quercetin/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rice flour placebo
Number of subjects: 0
Study: 8023779

Group type: EXPERIMENTAL
Intervention: Fluvastatin, 20 mg/day for 6 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fluvastatin + niacin (titrated to a maximum of 3 g/day for a further 9 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fluvastatin + niacin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fluvastatin (alone)
Number of subjects: 74
Study: 2584285

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study: 1097198

Group type: EXPERIMENTAL
Intervention: halcinonide 0.1%
Number of subjects: 100

Group type: COMPARATOR
Intervention: clobetasol propionate cream 0.05%
Number of subjects: 100
Study: 29519744

Group type: EXPERIMENTAL
Intervention: Light mask (Noctura 400 Sleep Mask)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Sham mask (non-light)
Number of subjects: 308
Study: 26970427

Group type: EXPERIMENTAL
Intervention: Severity of acute bronchiolitis measured by length of stay and need for ventilatory support
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Ventilatory support
Number of subjects: 209
Study: 25690336

Group type: EXPERIMENTAL
Intervention: Single-coil lead system
Number of subjects: 469

Group type: COMPARATOR
Intervention: Dual-coil lead system
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Anodal shock
Number of subjects: 469

Group type: COMPARATOR
Intervention: Cathodal shock
Number of subjects: 469
Study: 24341333

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study: 20536470

Group type: EXPERIMENTAL
Intervention: Topically administered Tbeta4 (0.03%)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 17993603

Group type: EXPERIMENTAL
Intervention: beta‐adrenergic blockade‐intravenous propranolol (0.2 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: parasympathetic blockade‐intravenous atropine (0.04 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: double blockade with propranolol and atropine
Number of subjects: 33

Group type: COMPARATOR
Intervention: baseline
Number of subjects: 33
Study: 16368440

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy (paclitaxel 135 mg/m² IV over 24 h, cisplatin 100 mg/m² IP day 2, paclitaxel 60 mg/m² IP day 8) every 21 days for six cycles
Number of subjects: 205

Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy (alternate regimen for patients unable to receive IP therapy)
Number of subjects: 205
Study: 12744096

Group type: EXPERIMENTAL
Intervention: Rubber band ligation + local anaesthetic injection (n = 70)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Rubber band ligation only (n = 72)
Number of subjects: 142
Study: 11199189

Group type: EXPERIMENTAL
Intervention: Lowest individual lumbar vertebra T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lumbar spine T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mid-forearm T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Distal forearm T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hip T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Correlation between skeletal sites
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Individual lumbar vertebra T-scores
Number of subjects: 150

Group type: COMPARATOR
Intervention: L2 T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: L4 T-score
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mean difference between L2 and L4 T-scores
Number of subjects: 150
Study: 9277382

Group type: COMPARATOR
Intervention: 14% plasma volume expansion (LOW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 21% plasma volume expansion (HIGH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0% plasma volume expansion (CON)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 8
Study: 8421077

Group type: EXPERIMENTAL
Intervention: 1 mg continuous sc GHRH 1-44 infusion daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg continuous sc GHRH 1-44 infusion daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 0
Study: 2935497

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d.
Number of subjects: 24
Study: 2684916

Group type: EXPERIMENTAL
Intervention: Exercise test on day 3
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (thrombolysis or coronary angioplasty or both)
Number of subjects: 126
Study: 31078312

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Complex segmentectomy
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: > 20 pack-years of smoking
Number of subjects: 1106
Study: 27852617

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 PUFA (3 g fish oil/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (3 g safflower oil/d)
Number of subjects: 50
Study: 26352860

Group type: EXPERIMENTAL
Intervention: DuoResp Spiromax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 0
Study: 24340537

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse 0.1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sterile water rinse
Number of subjects: 80
Study: 21467302

Group type: EXPERIMENTAL
Intervention: Continuous iv infusion of combined GHRH/GHRP‐2 during pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous iv infusion of combined GHRH/GHRP‐2
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Number of subjects: 25
Study: 20134217

Group type: EXPERIMENTAL
Intervention: Two cross K-wires (group 1; 7 patients, 8 feet)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Compressive screw (group 2; 6 patients, 8 feet)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study: 16672699

Group type: EXPERIMENTAL
Intervention: Primary stent implantation (self-expanding nitinol stent)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 104
Study: 14967081

Group type: EXPERIMENTAL
Intervention: Written handout added to verbal explanation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal explanation only (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific risk - Facial nerve paralysis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific risk - Complete hearing loss
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific risk - Dizziness
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific risk - Change in taste
Number of subjects: 50
Study: 10512076

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SAFE condition
Number of subjects: 12
Study: 7557823

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) every 8 hours for three days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1959004

Group type: EXPERIMENTAL
Intervention: Oxerutins (Paroven 500 mg twice daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both oxerutins and placebo (compliance with tablets and stockings)
Number of subjects: 138
Study: 7325407

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 37
Study: 30887623

Group type: EXPERIMENTAL
Intervention: Some family involvement in home-based care
Number of subjects: 0
Study: 28520962

Group type: EXPERIMENTAL
Intervention: Preoperative 1-week systematic high-intensity inpatient exercise regimen
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (standard preoperative care)
Number of subjects: 101
Study: 26573188

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg/day, oral)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adefovir (10 mg/day, oral)
Number of subjects: 90
Study: 23102599

Group type: EXPERIMENTAL
Intervention: High titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Low titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Number of subjects: 748
Study: 21615790

Group type: EXPERIMENTAL
Intervention: Colonoscopy-first group (n = 87)
Number of subjects: 176

Group type: COMPARATOR
Intervention: EGD-first group (n = 89)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 176
Study: 19055285

Group type: EXPERIMENTAL
Intervention: Bilateral Yongquan (KI 1) application with Biyankang Tablet, once each night
Number of subjects: 125

Group type: COMPARATOR
Intervention: 0.5% Ephedrine naristillae, one drop each nose each time, tid
Number of subjects: 125
Study: 16873326

Group type: EXPERIMENTAL
Intervention: Bilateral balanced splint
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Canine guidance splint
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonoccluding splint
Number of subjects: 57
Study: 12591005

Group type: EXPERIMENTAL
Intervention: Borage oil 3000 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil 3000 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil 1500 mg and borage oil 1500 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11045840

Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 628 +/- 254 mL of an energy supplement rich in fat (31% of energy) and linoleic acid (16% of energy) for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intensive dietary counseling only
Number of subjects: 36
Study: 8716526

Group type: EXPERIMENTAL
Intervention: Use of a jaundice meter to validate nurses' visual assessments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual assessments by nurses
Number of subjects: 0
Study: 1462745

Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination (3 oral nonabsorbable antibiotics: Neomycin 1 gr, Colistin 1.500.000 U, Nystatin 1.000.000 U every 6 hours for first 74 patients; Norfloxacin 400 mg BID for following patients) for at least 5 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 94
Study: 6239538

Group type: EXPERIMENTAL
Intervention: Low-dose chlorozotocin (120 mg/m2 if untreated, 100 mg/m2 if treated)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose chlorozotocin (200 mg/m2 if untreated, 175 mg/m2 if treated)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low-dose and high-dose chlorozotocin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose chlorozotocin
Number of subjects: 78
Study: 30828982

Group type: EXPERIMENTAL
Intervention: Heavy resistance training for 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untrained controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Young men (19-27 years), n = 9
Number of subjects: 29
Study: 30187978

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg for 1 week, then 1 mg for 11 weeks, twice daily)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo (identical unlabelled tablets for 12 weeks)
Number of subjects: 510
Study: 28423165

Group type: EXPERIMENTAL
Intervention: League tables
Number of subjects: 221

Group type: COMPARATOR
Intervention: Funnel plots
Number of subjects: 221
Study: 26242048

Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g, tid) combined with clomiphene (50 mg, qd)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clomiphene (50 mg, qd) alone
Number of subjects: 300
Study: 23482340

Group type: EXPERIMENTAL
Intervention: Medical treatment (methotrexate injection alone)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Conservative surgery with post-operative methotrexate injection
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 406

Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 406
Study: 20586147

Group type: EXPERIMENTAL
Intervention: Polarized light (PL) applied to neuropathic ulcers of diabetic foot twice daily for ten minutes for three months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Antioxidants (60 mg hydrosoluble CoQ10, 100 mg alpha‐lipoic acid (ALA), and 200 mg vitamin E) used in two daily doses for three months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Simultaneous application of PL and antioxidants
Number of subjects: 59
Study: 18818788

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM) by transient elastography with a cut-off value of 15.9 kPa for cirrhosis determination
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: High LSM group (LSM ≥ 15.9 kPa)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Low LSM group (LSM < 15.9 kPa)
Number of subjects: 386
Study: 16785773

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 64
Study: 12753150

Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 7